factual

Biotech in Europe struggles to raise capital

Biotech startups in Europe face particularly difficult funding because European investors are more risk averse than US investors, and Argenx survived for years on raises of no more than about $60 million.

factualpending

Speaker

Julia

Evidence Quote

“not more than $60 million before prop around for many, many years”

Source

Argenx: Changing Lives with Llamas— Business Breakdowns
Created: 11/17/2026, 3:39:21 AM

Your notes

Loading notes...